Besides, EGFR stimulation results in increasing the expression of VEGF (vascular endothelial growth factor) which is the main factor that is responsible for tumor angiogenesis after its binding to VEGFR-2 (vascular endothelial growth factor receptor-2).19 Therefore, FDA-approved VEGFR-2 inhibitors (e.g. sorafenib)20 are considered potential anticancer drugs, Fig. 1. The gene discussed is VEGFA; the disease is neoplasm.